secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001724521-25-000122
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones
--------------------------------------------------------------------------------

- First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.
- Up to $50M available after announcement of Phase 3 data supporting FDA filing; $50M after FDA approval.
- $50M available at company's sole option through March 2026 and September 2026 ($25M each).
- Maturity extended to September 1, 2030.
- Performance covenants apply if draws exceed $200M: market cap ≥ $1.5B or cash/revenue thresholds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000122/0001724521-25-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000122/rcus-20251218.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer